ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0264

Prevalence and Risk Factors Associated with Isolated Neutropenia in Outpatients with Systemic Lupus Erythematosus

Nouf Alhammadi1, Murray Urowitz2 and Dafna Gladman3, 1University of Toronto, Toronto, Canada, 2University Health Network, University of Toronto, Toronto, ON, Canada, 3Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada

Meeting: ACR Convergence 2020

Keywords: Cohort Study, Infection, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Friday, November 6, 2020

Title: SLE – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Manifestations

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Leukopenia in SLE is defined as leukocyte count below 4,000/mm3 on two or more occasions according to the ACR criteria and may include a combination of lymphopenia and neutropenia or either of these alone.  Neutropenia may be mild/moderate or severe and may be associated with increased susceptibility to infection. Our objective was to determine the prevalence and factors associated with isolated neutropenia in outpatients with SLE.

Methods: Retrospective analysis of prospectively collected data. Setting: Patients in our cohort are followed regularly at 2-6 months’ intervals according to a standardized research protocol which captures demographic, clinical, laboratory and therapeutic variables along with the major co-morbidities. All data are entered and stored in an electronic database. Neutropenia was defined as absolute neutrophil count (ANC) below 1,500/mm3. Mild/moderate neutropenia was defined as neutropenia ≥ 1000/mm3 and < 1500 /mm3) and severe neutropenia was a neutrophil count < 1000 / mm3. Patients with isolated neutropenia on at least 2 consecutive visits with gap between visits of ≤ 24 months were identified. The baseline characteristics of the patients were compared between patients who experienced isolated neutropenia and those with combined neutropenia and lymphopenia. The percent of infections and the rate of infection in the 2 groups was determined. Mean with standard deviation and median with interquartile ranges were used to describe continuous variables, counts with percentages were use to describe categorical variables, then variables were compared by Student’s t-test or Chi-Square test between groups.

Results: Of 2045 patients in the database, 170 (8.3%) were found to have neutropenia on 2 consecutive visits (visit gap ≤24 months) of whom, 30(1.4%) had severe neutropenia and the rest was mild to moderate. Isolated neutropenia was found in 35(1.9%) patients, 29 (82.9%) with mild moderate and 6 (17.1%) with severe neutropenia. Patients with isolated neutropenia and neutropenia with lymphopenia were similar except for Black ethnicity which was more common in isolated neutropenia and more patients taking azathioprine had neutropenia/lymphopenia (Table 1)

Infections occurred in 17,6% with no neutropenia, 6.5% with isolated neutropenia and 21.9% with neutropenia/lymphopenia. Kaplan Meier survival curves showed higher cumulative incidence of infection with no neutropenia and neutropenia/lymphopenia likely due to low numbers (Fig 1)

Conclusion: Isolated neutropenia is not prevalent in SLE patients in general but is more common in Blacks. Risk of infection didn’t increase in isolated neutropenia group compared to combined leucopenia and SLE patients without neutropenia.

Table1: Characteristics of patients with neutropenia.

Fig 1 Kaplan Meier curve for first infection.


Disclosure: N. Alhammadi, None; M. Urowitz, None; D. Gladman, AbbVie, 2, 5, Amgen, 2, 5, Janssen, 2, 5, Novartis, 2, 5, Pfizer, 2, 5, UCB, 2, 5, Bristol-Myers Squibb, 5, Gilead, 5, Galapagos, 5, Celgene, 2, 5, Eli Lilly, 2, 5.

To cite this abstract in AMA style:

Alhammadi N, Urowitz M, Gladman D. Prevalence and Risk Factors Associated with Isolated Neutropenia in Outpatients with Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/prevalence-and-risk-factors-associated-with-isolated-neutropenia-in-outpatients-with-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-and-risk-factors-associated-with-isolated-neutropenia-in-outpatients-with-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology